Sanofi to invest €350m in new Canadian vaccine plant

Sanofi has announced plans to spend €350 million on a new vaccine facility located in Toronto, Canada, a move which, according to the company, is one of its biggest-ever investments in a single building.

The French drugmaker said that the new facility would enable it to better meet the rising demand of five-component acellular pertussis (5-acP) antigen, and will also be equipped to manufacture the antigens used in the diphtheria and tetanus vaccines. The facility is due to be operational by 2021.

"Canada has a strong legacy in the research and development of vaccines.  With this investment, Sanofi is renewing our longstanding commitment to making Canada central in our effort to protect and improve human health across the globe," said David Loew, Executive Vice President and Head of Sanofi Pasteur. "Vaccines save three million lives every year and this new facility will take us one step closer to a world where no one suffers or dies from a vaccine-preventable disease."

Philippe Luscan, Executive Vice President, Global Industrial Affairs, added: "This project is one of the most important investments for the Sanofi global industrial network. It demonstrates our continued commitment to manufacturing excellence and to better serving our vaccines portfolio to people all over the world." 

Register as Visitor to CPhI China 2018!